Morten Grunnet
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
NaV1.5 or KCa2 channel blockade does not increase arrhythmia risk in hypokalemic rabbit hearts, unlike KV11.1 inhibition with dofetilide.
Journal: International journal of cardiology. Heart & vasculature
Published: March 27, 2025
Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial.
Journal: Nature medicine
Published: June 15, 2023
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation.
Journal: British journal of clinical pharmacology
Published: July 05, 2022
The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Journal: Journal of cardiovascular pharmacology
Published: May 27, 2020
In vitro and in vivo characterization of Lu AA41178: A novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders.
Journal: European journal of pharmacology
Published: May 07, 2020
Inhibition of KCa2 Channels Decreased the Risk of Ventricular Arrhythmia in the Guinea Pig Heart During Induced Hypokalemia.
Journal: Frontiers in pharmacology
Published: February 26, 2020
First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.
Journal: Clinical and translational science
Published: February 26, 2020
Inhibition of KCa2 and Kv11.1 Channels in Pigs With Left Ventricular Dysfunction.
Journal: Frontiers in pharmacology
Published: January 20, 2020
Characterization of Atrial and Ventricular Structural Remodeling in a Porcine Model of Atrial Fibrillation Induced by Atrial Tachypacing.
Journal: Frontiers in veterinary science
Published: December 26, 2019
The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.
Journal: Frontiers in pharmacology
Published: December 16, 2019
Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
Journal: Frontiers in pharmacology
Published: December 16, 2019
Impact of arrhythmogenic calmodulin variants on small conductance Ca2+ -activated K+ (SK3) channels.
Impact of arrhythmogenic calmodulin variants on small conductance Ca2+ -activated K+ (SK3) channels.
Journal: Physiological reports
Published: July 26, 2019
Last Updated: 09/26/2026